BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

MAP Pharmaceuticals, Inc. 

2400 Bayshore Parkway
Suite 200
Mountain View  California  94043  U.S.A.
Phone: 650-386-3100 Fax: 650-386-3101


SEARCH JOBS

View Clinical Trials from BioPharm Insight



 Key Statistics


Email:
Ownership: Public

Web Site: MAP Pharmaceuticals, Inc.
Employees:
Symbol: MAPP
 



Industry
Pharmaceutical






 Company News
Allergan Inc. (AGN) Announces Expiration of Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. (MAPP) and Intent to Exercise Top-Up Option to Effect a Short-Form Merger 3/1/2013 9:49:48 AM
Allergan Inc. (AGN) and MAP Pharmaceuticals, Inc. (MAPP) Announce the Federal Trade Commission Has Granted Early Termination of Waiting Period Under Hart-Scott-Rodino Act 2/7/2013 9:58:14 AM
Allergan Inc. (AGN) Commences Cash Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. (MAPP) 1/31/2013 10:24:52 AM
Allergan Inc. (AGN) to Buy MAP Pharmaceuticals, Inc. (MAPP) for $958 Million 1/23/2013 6:55:08 AM
MAP Pharmaceuticals, Inc. (MAPP) to Present at the 31st Annual J.P. Morgan Healthcare Conference 1/3/2013 7:28:36 AM
MAP Pharmaceuticals, Inc. (MAPP) Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX® 11/26/2012 8:46:46 AM
MAP Pharmaceuticals, Inc. (MAPP) to Present at Upcoming Investor Conferences 11/9/2012 2:15:18 PM
MAP Pharmaceuticals, Inc. (MAPP) Reports Third Quarter of 2012 Financial Results 11/2/2012 9:33:35 AM
MAP Pharmaceuticals, Inc. (MAPP) Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 10/16/2012 9:24:35 AM
MAP Pharmaceuticals, Inc. (MAPP) Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock 8/30/2012 10:17:01 AM
12345678910...